@article{2f8df034881540b7b16b41af27b77473,
title = "Consensus statement by the American association of clinical endocrinologists and American college of endocrinology on the comprehensive type 2 diabetes management algorithm - 2018 executive summary",
abstract = "This document represents the official position of the American Association of Clinical Endocrinologists and American College of Endocrinology. Where there were no randomized controlled trials or specific U.S. FDA labeling for issues in clinical practice, the participating clinical experts utilized their judgment and experience. Every effort was made to achieve consensus among the committee members. Position statements are meant to provide guidance, but they are not to be considered prescriptive for any individual patient and cannot replace the judgment of a clinician.",
author = "Garber, {Alan J.} and Abrahamson, {Martin J.} and Barzilay, {Joshua I.} and Lawrence Blonde and Bloomgarden, {Zachary T.} and Bush, {Michael A.} and Samuel Dagogo-Jack and DeFronzo, {Ralph A.} and Daniel Einhorn and Fonseca, {Vivian A.} and Garber, {Jeffrey R.} and Garvey, {W. Timothy} and George Grunberger and Yehuda Handelsman and Hirsch, {Irl B.} and Jellinger, {Paul S.} and McGill, {Janet B.} and Mechanick, {Jeffrey I.} and Rosenblit, {Paul D.} and Umpierrez, {Guillermo E.}",
note = "Funding Information: Dr. Irl B. Hirsch reports that he is a consultant for Abbott, Adocia, Intarcia, Bigfoot, and Roche. He has also received research grant support from Medtronic. Funding Information: Dr. Samuel Dagogo-Jack reports that he is a consultant for Merck, Janssen, AstraZeneca, and Sanofi. He owns stock with Dance Pharma and Janacare. He has also received research grant support to the University of Tennessee from AstraZeneca, Novo Nordisk, and Boehringer Ingelheim. Funding Information: Dr. Daniel Einhorn reports that he is a consultant for Lilly, Novo Nordisk, Sanofi, Takeda, Halozyme, AstraZeneca, Adocia, Epitracker, GlySens, and Janssen. He is a speaker for Abbott. He owns stock with Halozyme and has options with Nexus BioPharma, Epitracker, and GlySens. He has also received research grant support from Novo Nordisk, Lilly, AstraZeneca, Janssen, and Sanofi. Funding Information: Dr. Ralph A. DeFronzo reports that he is a consultant for Boehringer Ingelheim, AstraZeneca, Novo Nordisk, Janssen, Intarcia, and Elcelyx. He is a speaker for Novo Nordisk, AstraZeneca, and Merck. He has also received grant research support from Bristol Myers Squibb, Boehringer Ingelheim, Janssen, and AstraZeneca. Funding Information: Dr. Janet B. McGill reports that she is a consultant for Aegerion, Dexcom, Novo Nordisk, Intarcia, Valeritas, and Boehringer Ingelheim. She is a speaker for Aegerion, Dexcom, and Mannkind. She has received research grant support from Novartis, AstraZeneca, Bristol Myers Squibb, the Leona Helmsley Trust, and the National Institutes of Health. Funding Information: Dr. W. Timothy Garvey reports that he is a consultant for AstraZeneca, Janssen, Eisai, Takeda, Novo Nordisk, Alexion, and Merck. He has also received research grants from Merck, Weight Watchers, Sanofi, Eisai, AstraZeneca, Lexicon, Pfizer, and Novo Nordisk. Dr. Garvey is a shareholder in ISIS Pharmaceuticals, Novartis, Bristol Myers Squibb, Pfizer, Merck, and Eli Lilly. Funding Information: Dr. Guillermo E. Umpierrez reports that he is a consultant for Sanofi, Merck, and Glytec. He has also received research grant support to Emory University from AstraZeneca, Boehringer Ingelheim, Merck, Novo Nordisk, and Sanofi. Funding Information: Dr. Yehuda Handelsman reports that he is a consultant for Amarin, Amgen, AstraZeneca, Boehringer Ingelheim (BI), Janssen, Eli Lilly, Eisai, Intarcia, Merck, Novo Nordisk, Sanofi, and Regeneron. He is a speaker for Amarin, Amgen, AstraZeneca, Boehringer Ingelheim-Lilly, Janssen, Novo Nordisk, and Sanofi. He has also received research grant support from Amgen, AstraZeneca, Boehringer Ingelheim, Gan & Lee, Lexicon, Merck, Novo Nordisk, and Sanofi. Funding Information: Dr. Lawrence Blonde reports that he is a consultant for AstraZeneca, GlaxoSmithKline, Intarcia, Janssen, Merck, Novo Nordisk, and Sanofi. He is also a speaker for AstraZeneca, Janssen, Merck, Novo Nordisk, and Sanofi. Dr. Blonde has received research grant support from AstraZeneca, Janssen, Lexicon Pharmaceuticals, Merck, Novo Nordisk, and Sanofi. Funding Information: He owns stock with Amgen. He has also received research grant support from Asahi, Abbott, and Bayer. Publisher Copyright: {\textcopyright} 2018 AACE.",
year = "2018",
month = jan,
doi = "10.4158/CS-2017-0153",
language = "English",
volume = "24",
pages = "91--120",
journal = "Endocrine Practice",
issn = "1530-891X",
number = "1",
}